Risankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, UltIMMa-2, and IMMvent) risankizumab demonstrated early and sustained efficacy at 12-week dosing in patients with moderate-to-severe psoriasis.1,2 To date, limited real-life data are available on its effectiveness and safety.

Hansel, K., Zangrilli, A., Bianchi, L., Peris, K., Chiricozzi, A., Offidani, A., et al. (2021). A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 35(3), 169-170 [10.1111/jdv.17003].

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic

Zangrilli, A;Bianchi, L;
2021-10-20

Abstract

Risankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, UltIMMa-2, and IMMvent) risankizumab demonstrated early and sustained efficacy at 12-week dosing in patients with moderate-to-severe psoriasis.1,2 To date, limited real-life data are available on its effectiveness and safety.
20-ott-2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
COVID-19
Psoriasis
effectiveness
real-life
risankizumab
safety
Hansel, K., Zangrilli, A., Bianchi, L., Peris, K., Chiricozzi, A., Offidani, A., et al. (2021). A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 35(3), 169-170 [10.1111/jdv.17003].
Hansel, K; Zangrilli, A; Bianchi, L; Peris, K; Chiricozzi, A; Offidani, A; Diotallevi, F; Fargnoli, Mc; Esposito, M; Amerio, P; Gualdi, G; Bianchi, L;...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
hansel risankizumab.pdf

solo utenti autorizzati

Tipologia: Documento in Pre-print
Licenza: Copyright dell'editore
Dimensione 4.13 MB
Formato Adobe PDF
4.13 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/255413
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 34
social impact